Tag Archives: Bial

Club Phase 1, a group representing early clinical development stakeholders in France, held their 16th Annual Meeting in Paris on 22nd March. Topics ranged from dealing with immunogenicity to Drug Drug Interactions and a session led by a Biotrial representative … Continue reading →